(Q53536405)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16729353%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16729353%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16729353%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16729353%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Annika Loft

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16729353%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Mads Hansen

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16729353%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Elisabeth Ralfkiaer

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16729353%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

1 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16729353%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

published in

Hematological Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16729353%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16729353%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16729353%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

146-150

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16729353%20AND%20SRC:MED&resulttype=core&format=json

FDG-PET in the clinical management of Hodgkin lymphoma.

28 January 2020

cites work

1 reference

Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease

21 January 2018

1 reference

7 January 2021

Positron emission tomography for the staging of Hodgkin's lymphoma--increasing the body of evidence in favor of the method

1 reference

7 January 2021

2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution

1 reference

7 January 2021

Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease

1 reference

7 January 2021

Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease

1 reference

7 January 2021

Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease

1 reference

7 January 2021

Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma

1 reference

7 January 2021

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

1 reference

7 January 2021

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

1 reference

7 January 2021

Intensity-modulated radiotherapy for lymphoma involving the mediastinum

1 reference

7 January 2021

Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose c

1 reference

7 January 2021

Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT).

1 reference

7 January 2021

FDG-PET in radiotherapy treatment planning: Pandora's box?

1 reference

7 January 2021

Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer

1 reference

7 January 2021

The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study

1 reference

7 January 2021

18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis

1 reference

7 January 2021

2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography in target volume definition for radiotherapy of patients with non-small-cell lung cancer

1 reference

7 January 2021

Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.

1 reference

7 January 2021

Positron Emission Tomography in Patients with Hodgkin's Disease: Correlation to Histopathologic Subtypes

1 reference

7 January 2021

Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma

1 reference

7 January 2021

Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume.

1 reference

7 January 2021

The role of positron emission tomography in radiation treatment planning

1 reference

7 January 2021

Identifiers

DOI

10.1002/HON.782

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16729353%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16729353%20AND%20SRC:MED&resulttype=core&format=json